Regulation of prostate branching morphogenesis by activin A and follistatin

被引:61
作者
Cancilla, B
Jarred, RA
Wang, H
Mellor, SL
Cunha, GR
Risbridger, GP [1 ]
机构
[1] Monash Univ, Monash Inst Reprod & Dev, Clayton, Vic 3168, Australia
[2] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA
基金
英国医学研究理事会;
关键词
activin; follistatin; prostate; branching morphogenesis;
D O I
10.1006/dbio.2001.0364
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Ventral prostate development occurs by branching morphogenesis and is an androgen-dependent process modulated by growth factors. Many growth factors have been implicated in branching morphogenesis including activins (dimers of beta (A) and beta (B) subunits); activin A inhibited branching of lung and kidney in vitro. Our aim was to examine the role of activins on prostatic development in vitro and their localization in vivo. Organ culture of day 0 rat ventral prostates for 6 days with activin A (+/- testosterone) inhibited prostatic branching and growth without increasing apoptosis. The activin-binding protein follistatin increased branching in vitro in the absence (but not presence) of testosterone, suggesting endogenous activins may reduce prostatic branching morphogenesis. In vivo, inhibin subunit was not expressed until puberty, therefore inhibins (dimers of alpha and beta subunits) are not involved in prostatic development. Activin beta (A) was immunolocalized to developing prostatic epithelium and mesenchymal aggregates at ductal tips. Activin beta (B) immunoreactivity was weak during development, but was upregulated in prostatic epithelium during puberty. Activin receptors were expressed throughout the prostatic epithelium. Follistatin mRNA and protein were expressed throughout the prostatic epithelium. The in vitro evidence that activin and follistatin have opposing effects on ductal branching suggests a role for activin as a negative regulator of prostatic ductal branching morphogenesis. (C) 2001 Academic Press.
引用
收藏
页码:145 / 158
页数:14
相关论文
共 65 条
  • [1] ALBANO RM, 1990, DEVELOPMENT, V110, P435
  • [2] Bellusci S, 1997, DEVELOPMENT, V124, P4867
  • [3] A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse
    Nolan, PM
    Peters, J
    Strivens, M
    Rogers, D
    Hagan, J
    Spurr, N
    Gray, IC
    Vizor, L
    Brooker, D
    Whitehill, E
    Washbourne, R
    Hough, T
    Greenaway, S
    Hewitt, M
    Liu, XH
    McCormack, S
    Pickford, K
    Selley, R
    Wells, C
    Tymowska-Lalanne, Z
    Roby, P
    Glenister, P
    Thornton, C
    Thaung, C
    Stevenson, JA
    Arkell, R
    Mburu, P
    Hardisty, R
    Kiernan, A
    Erven, H
    Steel, KP
    Voegeling, S
    Guenet, JL
    Nickols, C
    Sadri, R
    Naase, M
    Isaacs, A
    Davies, K
    Browne, M
    Fisher, EMC
    Martin, J
    Rastan, S
    Brown, SDM
    Hunter, J
    [J]. NATURE GENETICS, 2000, 25 (04) : 440 - 443
  • [4] BURGER HG, 1988, CLIN ENDOCRINOL, V28, P448
  • [5] Discrete cell- and stage-specific localisation of fibroblast growth factors and receptor expression during testis development
    Cancilla, B
    Davies, A
    Ford-Perriss, M
    Risbridger, GP
    [J]. JOURNAL OF ENDOCRINOLOGY, 2000, 164 (02) : 149 - 159
  • [6] TYPE-I RECEPTORS SPECIFY GROWTH-INHIBITORY AND TRANSCRIPTIONAL RESPONSES TO TRANSFORMING GROWTH-FACTOR-BETA AND ACTIVIN
    CARCAMO, J
    WEIS, FMB
    VENTURA, F
    WIESER, R
    WRANA, JL
    ATTISANO, L
    MASSAGUE, J
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (06) : 3810 - 3821
  • [7] Chinoy MR, 1998, PEDIATR PULM, V25, P244, DOI 10.1002/(SICI)1099-0496(199804)25:4<244::AID-PPUL5>3.0.CO
  • [8] 2-K
  • [9] CUNHA GR, 1995, WORLD J UROL, V13, P264
  • [10] INHIBIN
    DEJONG, FH
    [J]. PHYSIOLOGICAL REVIEWS, 1988, 68 (02) : 555 - 607